Mansouri Alireza, Ozair Ahmad, Bhanja Debarati, Wilding Hannah, Mashiach Elad, Haque Waqas, Mikolajewicz Nicholas, de Macedo Filho Leonardo, Mahase Sean S, Machtay Mitchell, Metellus Philippe, Dhermain Frédéric, Sheehan Jason, Kondziolka Douglas, Lunsford L Dade, Niranjan Ajay, Minniti Giuseppe, Li Jing, Kalkanis Steven N, Wen Patrick Y, Kotecha Rupesh, McDermott Michael W, Bettegowda Chetan, Woodworth Graeme F, Brown Paul D, Sahgal Arjun, Ahluwalia Manmeet S
Department of Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
Penn State Cancer Institute, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
Nat Rev Clin Oncol. 2025 May;22(5):327-347. doi: 10.1038/s41571-025-01013-1. Epub 2025 Mar 19.
The management of brain metastases is challenging and should ideally be coordinated through a multidisciplinary approach. Stereotactic radiosurgery (SRS) has been the cornerstone of management for most patients with oligometastatic central nervous system involvement (one to four brain metastases), and several technological and therapeutic advances over the past decade have broadened the indications for SRS to include polymetastatic central nervous system involvement (>4 brain metastases), preoperative application and fractionated SRS, as well as combinatorial approaches with targeted therapy and immune-checkpoint inhibitors. For example, improved imaging and frameless head-immobilization technologies have facilitated fractionated SRS for large brain metastases or postsurgical cavities, or lesions in proximity to organs at risk. However, these opportunities come with new challenges and questions, including the implications of tumour histology as well as the role and sequencing of concurrent systemic treatments. In this Review, we discuss these advances and associated challenges in the context of ongoing clinical trials, with insights from a global group of experts, including recommendations for current clinical practice and future investigations. The updates provided herein are meaningful for all practitioners in clinical oncology.
脑转移瘤的管理具有挑战性,理想情况下应通过多学科方法进行协调。立体定向放射外科(SRS)一直是大多数寡转移中枢神经系统受累(1至4个脑转移瘤)患者管理的基石,在过去十年中,多项技术和治疗进展拓宽了SRS的适应证,包括多转移中枢神经系统受累(>4个脑转移瘤)、术前应用和分次SRS,以及与靶向治疗和免疫检查点抑制剂的联合应用。例如,改进的成像和无框架头部固定技术促进了对大脑大转移瘤、术后腔隙或临近危险器官病变的分次SRS。然而,这些机遇伴随着新的挑战和问题,包括肿瘤组织学的影响以及同期全身治疗的作用和顺序。在本综述中,我们结合正在进行的临床试验来讨论这些进展和相关挑战,并听取了全球专家小组的见解,包括对当前临床实践和未来研究的建议。本文提供的更新内容对所有临床肿瘤学从业者都具有重要意义。